---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053900"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:57:44.112470+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IDEAYA Q1 net loss $39.6M, cash $941M; darovasertib UM data at ASCO, Werner IND on track

## Summary
- Net loss of $39.6M for Q1 2024; cash, equivalents and marketable securities $941.4M, projected to fund operations into 2028.
- Darovasertib neoadjuvant UM Phase 2 IST oral presentation at ASCO 2024; company-sponsored update on >30 patients and FDA guidance targeted H2 2024.
- Selected Phase 2 dose for IDE397 in MTAP-deletion squamous NSCLC based on multiple PRs by RECIST 1.1; multiple PRs also in MTAP bladder cancer.
- IND-enabling GLP tox completed for Werner Helicase inhibitor with GSK; IND filing targeted H2 2024 as 5th first-in-class clinical program.
- Targeting FPI for IDE397+Trodelvy in MTAP bladder cancer mid-2024; Phase 2 expansion for IDE161 in HRD and combo with KEYTRUDA in endometrial cancer in H2 2024.

## SEC filing metadata
- accession: 0000950170-24-053900
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017024053900/0000950170-24-053900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017024053900/idya-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053900
- JSON: https://secwatch.observer/filing/0000950170-24-053900.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053900.txt

## Key facts
- Earnings Releases
  IDEAYA Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 7, 2024, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000095017024053900/0000950170-24-053900-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.